Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crescendo Biologics Evolves in Immuno-Oncology Under New Management

This article was originally published in Scrip

Executive Summary

First convinced as an investor by flourishing technology at Crescendo Biologics, Peter Pack has since been wooed to take up the position of CEO at the company. In a recent interview Pack told Scrip of his plans for transforming the firm from a resourceful technology platform business to a fully fledged oncology drug discovery company.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel